CRISPR Therapeutics AG (CRSP) Financials

Key financial figures for CRISPR Therapeutics AG (Q2 2026).

Revenue
$10M
Net Income
-$91M
EPS
$-0.94
Total Assets
$2.7B
Operating Cash Flow
-$83M

Full income statement, balance sheet, and cash flow for CRISPR Therapeutics AG on SentiSense.